Evidence map›Paper›PMID 41781380›Full record

ArticleSignal transduction and targeted therapy2026

Unleashing the potential of bimetallic nanobomb-mediated STING pathway to enhance bispecific T-cell engager against colorectal cancer photo-immunotherapy.

Min Mu, Hui Li, Bo Chen, Rangrang Fan, Kunhong Zhong, Guoqing Wang, Chenqian Feng, Nianyong Chen, Gang Guo, Aiping Tong and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Signal transduction and targeted therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Min MuDepartment of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
Hui LiDepartment of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
Bo ChenDepartment of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
Rangrang FanDepartment of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
Kunhong ZhongDepartment of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
Guoqing WangDepartment of Ophthalmology, West China Hospital, Sichuan University, Chengdu, China.
Chenqian FengDepartment of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
Nianyong ChenDepartment of Laboratory of Cancer Therapy and Immunity, Department of Radiation Oncology and Department of Head and Neck Oncology, West China Hospital, Sichuan University, Chengdu, China.
Gang GuoDepartment of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China. guogang@scu.edu.cn.ORCID http://orcid.org/0000-0002-4440-6366
Aiping TongDepartment of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China. aipingtong@scu.edu.cn.ORCID http://orcid.org/0000-0002-3392-5443
Bingwen ZouDepartment of Laboratory of Cancer Therapy and Immunity, Department of Radiation Oncology and Department of Head and Neck Oncology, West China Hospital, Sichuan University, Chengdu, China. zoubingwen81@163.com.ORCID http://orcid.org/0000-0002-0825-3657

Funding

National Natural Science Foundation of China (National Science Foundation of China) 31971308, 81960769 and U1903211Sichuan Provincial Department of Science and Technology | Sichuan Province Science and Technology Support Program 22GJHZ0015
6 · The paper itself

Abstract

The broader clinical application of Bispecific T-cell engagers (BiTEs) is hindered by their short half-life, on-target off-tumor toxicity, and limited therapeutic effect for solid tumors. Herein, we constructed a bimetallic-enriched triple-kill nanobomb manganese/Co

Indexed as

Colorectal NeoplasmsImmunotherapyMembrane ProteinsPhotothermal TherapyT-LymphocytesAnimalsB7-H1 AntigenCell Line, TumorcGAS-STING Signaling PathwayHumansMiceSTING ProteinTumor MicroenvironmentB7-H1 AntigenMembrane ProteinsSTING1 protein, humanSTING Protein

Identifiers

PMID41781380
PMCPMC12960729

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.